Schwartz Investment Counsel’s Regeneron Pharmaceuticals REGN Stock Holding History

Schwartz Investment Counsel’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$561K	Sell	900 -200	-18%	-$136K	0.02%	114
2026 Q1	$850K	Hold	1,100	–	–	0.03%	106
2025 Q4	$849K	Hold	1,100	–	–	0.03%	112
2025 Q3	$618K	Buy	1,100 +125	+13%	+$70.7K	0.02%	114
2025 Q2	$512K	Buy	975 +175	+22%	+$97.7K	0.02%	107
2025 Q1	$507K	Hold	800	–	–	0.02%	109
2024 Q4	$570K	Buy	800 +400	+100%	+$336K	0.02%	111
2024 Q3	$420K	Hold	400	–	–	0.02%	117
2024 Q2	$420K	Hold	400	–	–	0.02%	119
2024 Q1	$385K	Hold	400	–	–	0.01%	129
2023 Q4	$351K	Hold	400	–	–	0.01%	127
2023 Q3	$329K	Sell	400 -325	-45%	-$255K	0.01%	128
2023 Q2	$521K	Hold	725	–	–	0.02%	118
2023 Q1	$596K	Hold	725	–	–	0.03%	117
2022 Q4	$523K	Hold	725	–	–	0.02%	117
2022 Q3	$499K	Hold	725	–	–	0.03%	110
2022 Q2	$429K	Hold	725	–	–	0.02%	117
2022 Q1	$506K	Hold	725	–	–	0.02%	117
2021 Q4	$458K	Buy	725 +175	+32%	+$108K	0.02%	118
2021 Q3	$333K	Hold	550	–	–	0.01%	120
2021 Q2	$307K	Hold	550	–	–	0.01%	122
2021 Q1	$260K	Buy	+550	New	+$268K	0.01%	122

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Schwartz Investment Counsel's REGN Position: Q2 2026 in Review

Schwartz Investment Counsel reduced its Regeneron Pharmaceuticals (REGN) stake by 18% in Q2 2026, selling an estimated $136K and leaving 900 shares worth $561K. The position accounts for 0.02% of the portfolio, ranked #114.

Schwartz Investment Counsel first reported a position in REGN in Q1 2021 and has held it in 22 quarters since. The position peaked at $850K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Schwartz Investment Counsel held 900 shares of Regeneron Pharmaceuticals worth $561K as of Q2 2026.
Schwartz Investment Counsel sold 200 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $136K.
Regeneron Pharmaceuticals made up 0.02% of Schwartz Investment Counsel's portfolio in Q2 2026, its #114 holding.
Schwartz Investment Counsel first reported a position in Regeneron Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
Schwartz Investment Counsel's Regeneron Pharmaceuticals position peaked at $850K in Q1 2026.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Schwartz Investment Counsel's 13F filing for Q2 2026, filed 27 Jul 2026.